AR036327A1 - COMPOUNDS DERIVED FROM THE CHROMAN FOR THERAPEUTIC USE, PHARMACEUTICAL COMPOSITION, USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES TO TREAT MIGRANTS, RELATED COMPOUNDS, AND PROCESSES TO PREPARE THOSE RELATED COMPOUNDS - Google Patents

COMPOUNDS DERIVED FROM THE CHROMAN FOR THERAPEUTIC USE, PHARMACEUTICAL COMPOSITION, USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES TO TREAT MIGRANTS, RELATED COMPOUNDS, AND PROCESSES TO PREPARE THOSE RELATED COMPOUNDS

Info

Publication number
AR036327A1
AR036327A1 ARP020100142A ARP020100142A AR036327A1 AR 036327 A1 AR036327 A1 AR 036327A1 AR P020100142 A ARP020100142 A AR P020100142A AR P020100142 A ARP020100142 A AR P020100142A AR 036327 A1 AR036327 A1 AR 036327A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
compounds
alkyl
nha
related compounds
Prior art date
Application number
ARP020100142A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103646A external-priority patent/SE0103646D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR036327A1 publication Critical patent/AR036327A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Un compuesto que tiene la fórmula (1), donde: R1 es, en cualquier posición e independientemente, hidrógeno, alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, tiometoxi, -NHA, -NA2, -NHC(=O)A, aminocarbonilo, -C(=O)NHA, -C(=O)NA2, halógeno, hidroxi, -OA, ciano o arilo; A es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alquenilo opcionalmente sustituido o alquinilo opcionalmente sustituido; R2 es de fórmula (2); R3 es, independientemente y en cada posición, -H, alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 opcionalmente sustituido, alquinilo C2-6 opcionalmente sustituido, cicloalquilo C3-6 opcionalmente sustituido o AOH; n es 2, 3 ó 4; P es un anillo heterocíclico; R6 es -H o metilo; Y es -C(=O)NH-, -C(=O)NA-, -NHC(=O)-, -C(=S)NH-, -CH2NH-, -C(=O)-C(=O)CH2-, -CH2C(=O)-, -C(=O)-piperazina, -NAC(=O)-, -C(=S)N(A)-, -CH2NA-, -NACH2- o un heterociclo de 5 miembros; R7 es un anillo aromático monocíclico o bicíclico o un heterociclo opcionalmente sustituido con uno o más sustituyentes seleccionados de R8-R9 y R10; donde R7 está unido a Y ya sea por un enlace simple o por una fusión de anillos; R8 es -CH2-, -C(=O)-, -SO2-, -SO2NH-, -C(=O)NH, -O-, -S-, -S(=O)-, un enlace simple como ligadura desde R7 a R9, un heterociclo de 5 miembros unido a R7 por una fusión de anillos o un enlace simple como ligadura; R9 es heterociclo opcionalmente sustituido, arilo opcionalmente sustituido, piperazinil-R11 opcionalmente sustituido, morfolinil-R11 opcionalmente sustituido, tiomorfolinilo opcionalmente sustituido o -C(=O)A; R10 es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, hidroxi, arilo, ciano, halógeno, -C(=O)NH2-, metiltio, -NHA, -NA2, -NHC(=O)A, C(=O)NHA, C(=O)NA2, u OA; R11 es -H, alquilo, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C(=O)R9, -alquilR9, C(=O)A, C(=O)NH2, C(=O)NHA, C(=O)NA2 o -C(=O)OA; o una sal farmacéuticamente aceptable de dicho compuesto; composición farmacéutica, uso de estos compuestos para la preparación de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados.A compound having the formula (1), where: R1 is, in any position and independently, hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, thiomethoxy, -NHA, -NA2, -NHC (= O) A, aminocarbonyl, - C (= O) NHA, -C (= O) NA2, halogen, hydroxy, -OA, cyano or aryl; A is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl; R2 is of formula (2); R3 is, independently and in each position, -H, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C2-6 alkynyl, optionally substituted C3-6 cycloalkyl or AOH; n is 2, 3 or 4; P is a heterocyclic ring; R6 is -H or methyl; Y is -C (= O) NH-, -C (= O) NA-, -NHC (= O) -, -C (= S) NH-, -CH2NH-, -C (= O) -C ( = O) CH2-, -CH2C (= O) -, -C (= O) -piperazine, -NAC (= O) -, -C (= S) N (A) -, -CH2NA-, -NACH2- or a 5-member heterocycle; R7 is a monocyclic or bicyclic aromatic ring or a heterocycle optionally substituted with one or more substituents selected from R8-R9 and R10; where R7 is linked to Y either by a simple bond or by a fusion of rings; R8 is -CH2-, -C (= O) -, -SO2-, -SO2NH-, -C (= O) NH, -O-, -S-, -S (= O) -, a simple bond such as ligation from R7 to R9, a 5-membered heterocycle linked to R7 by a ring fusion or a single bond as ligation; R9 is optionally substituted heterocycle, optionally substituted aryl, optionally substituted piperazinyl-R11, optionally substituted morpholinyl-R11, optionally substituted thiomorpholinyl or -C (= O) A; R10 is optionally substituted alkyl, optionally substituted cycloalkyl, hydroxy, aryl, cyano, halogen, -C (= O) NH2-, methylthio, -NHA, -NA2, -NHC (= O) A, C (= O) NHA, C (= O) NA2, or OA; R11 is -H, alkyl, AOH, -SO2A, -SO2NH2, -SO2NHA, -SO2NA2, -SO2NHAR9, -C (= O) R9, -alkyl R9, C (= O) A, C (= O) NH2, C (= O) NHA, C (= O) NA2 or -C (= O) OA; or a pharmaceutically acceptable salt of said compound; pharmaceutical composition, use of these compounds for the preparation of drugs to treat migraine, related compounds, and processes for preparing those related compounds.

ARP020100142A 2001-01-16 2002-01-16 COMPOUNDS DERIVED FROM THE CHROMAN FOR THERAPEUTIC USE, PHARMACEUTICAL COMPOSITION, USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES TO TREAT MIGRANTS, RELATED COMPOUNDS, AND PROCESSES TO PREPARE THOSE RELATED COMPOUNDS AR036327A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26210801P 2001-01-16 2001-01-16
SE0103646A SE0103646D0 (en) 2001-11-01 2001-11-01 Therapeutic chroman compounds

Publications (1)

Publication Number Publication Date
AR036327A1 true AR036327A1 (en) 2004-09-01

Family

ID=26655581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100142A AR036327A1 (en) 2001-01-16 2002-01-16 COMPOUNDS DERIVED FROM THE CHROMAN FOR THERAPEUTIC USE, PHARMACEUTICAL COMPOSITION, USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES TO TREAT MIGRANTS, RELATED COMPOUNDS, AND PROCESSES TO PREPARE THOSE RELATED COMPOUNDS

Country Status (15)

Country Link
EP (1) EP1353915A2 (en)
JP (1) JP4280068B2 (en)
KR (1) KR20030070917A (en)
CN (1) CN100384833C (en)
AR (1) AR036327A1 (en)
AU (1) AU2002225551B8 (en)
BR (1) BR0206514A (en)
CA (1) CA2434015A1 (en)
IL (3) IL156601A0 (en)
MX (1) MXPA03006261A (en)
MY (1) MY138263A (en)
NO (1) NO20033205L (en)
NZ (1) NZ526699A (en)
SA (1) SA02220709B1 (en)
WO (1) WO2002055014A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344296B1 (en) 1996-08-08 2002-02-05 Hitachi Chemical Company, Ltd. Graphite particles and lithium secondary battery using the same as negative electrode
SE0103649D0 (en) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5149009B2 (en) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド Pyridazine derivatives for inhibiting human stearoyl-CoA desaturase
MX2007003327A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase.
JP5043668B2 (en) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heterocyclic derivatives and their use as therapeutic agents
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
BRPI0515483A (en) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives for the treatment of stearoyl coa desaturase mediated diseases
MX2007003332A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
MX2007015216A (en) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors.
UY29892A1 (en) * 2005-11-04 2007-06-29 Astrazeneca Ab NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
BRPI0619514A2 (en) 2005-12-08 2011-10-04 Millennium Pharm Inc bicyclic compounds with kinase inhibitory activity, pharmaceutical composition containing them and use of said compounds
AR059356A1 (en) * 2006-02-14 2008-03-26 Astrazeneca Ab NEW RADIOLIGANDS
WO2007097697A1 (en) * 2006-02-23 2007-08-30 Astrazeneca Ab Therapeutic quinoline compounds that are 5ht1b modulators
US7812206B2 (en) 2006-03-21 2010-10-12 Bp Corporation North America Inc. Apparatus and process for the separation of solids and liquids
US8530716B2 (en) 2008-08-14 2013-09-10 Bp Corporation North America Inc. Melt-crystallization separation and purification process
HUP0900281A2 (en) * 2009-05-05 2011-01-28 Univ Szegedi Kynurenc acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use for the treatment of headache
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
CN104262249A (en) * 2014-10-20 2015-01-07 云南民族大学 Environmental-friendly and efficient preparation method of quinolone compound
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
CN110198935B (en) 2017-01-23 2022-05-31 卡登特治疗公司 Potassium channel modulators
BR112021007552A2 (en) 2018-10-22 2021-07-27 Cadent Therapeutics, Inc. crystal forms of potassium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8515389D0 (en) * 1985-06-18 1985-07-17 Ici Plc Heterocyclic compounds
US5112856A (en) * 1986-08-15 1992-05-12 Hoffmann-La Roche Inc. Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives
SE8904361D0 (en) * 1989-12-22 1989-12-22 Astra Ab NEW CHROMAN AND THIOCHROMAN DERIVATIVES
DE4140542A1 (en) * 1991-12-09 1993-06-17 Bayer Ag PIPERDYLMETHYL SUBSTITUTED CHORMANDERIVATE
FR2761358B1 (en) * 1997-03-27 1999-05-07 Adir NOVEL N-ARYL PIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE9703378D0 (en) * 1997-09-18 1997-09-18 Astra Ab New compounds
FR2782515B1 (en) * 1998-08-21 2000-09-22 Adir NEW INDANE-1-Ol DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
SA02220709B1 (en) 2007-01-23
WO2002055014A2 (en) 2002-07-18
JP2004517130A (en) 2004-06-10
MXPA03006261A (en) 2003-09-22
AU2002225551B2 (en) 2008-04-03
WO2002055014A3 (en) 2002-11-14
BR0206514A (en) 2004-01-06
NO20033205L (en) 2003-09-02
EP1353915A2 (en) 2003-10-22
MY138263A (en) 2009-05-29
CN1524077A (en) 2004-08-25
CA2434015A1 (en) 2002-07-18
KR20030070917A (en) 2003-09-02
IL156601A0 (en) 2004-01-04
NZ526699A (en) 2005-03-24
CN100384833C (en) 2008-04-30
IL156601A (en) 2009-06-15
IL183183A0 (en) 2007-08-19
JP4280068B2 (en) 2009-06-17
AU2002225551B8 (en) 2008-05-29
NO20033205D0 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
AR036327A1 (en) COMPOUNDS DERIVED FROM THE CHROMAN FOR THERAPEUTIC USE, PHARMACEUTICAL COMPOSITION, USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES TO TREAT MIGRANTS, RELATED COMPOUNDS, AND PROCESSES TO PREPARE THOSE RELATED COMPOUNDS
AR035733A1 (en) THERAPEUTIC HETEROCICLIC COMPOUNDS, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES, RELATED COMPOUNDS AND PROCEDURES TO PREPARE THESE RELATED COMPOUNDS
AR035732A1 (en) CHROMEN-2-CARBOXYLIC THERAPEUTIC DERIVATIVES, USE OF THESE DERIVATIVES FOR THE PREPARATION OF MEDICINES, PHARMACEUTICAL COMPOSITION, RELATED COMPOUNDS, AND PROCESSES TO PREPARE THESE RELATED COMPOUNDS
PE20220931A1 (en) PYRAZOLO[3,4-B]PYRAZINE-TYPE SHP2 PHOSPHATASE INHIBITORS
CN104334563B (en) 7 oxothiazoiium pyridine carbonic acid derivative and their purposes in treatment, improvement or prevention virus disease
CO5580770A2 (en) THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT ANTAGONIST PROPERTIES
CO5580826A2 (en) THERAPEUTIC QUINOLONA COMPOUNDS WITH 5HT ANTAGONIST PROPERTIES
AR064608A1 (en) SUBSTITUTED PIRAZOLO-QUINAZOLINA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. PROCESS FOR THE PREPARATION AND USE OF THE SAME AS ANTICANCER AGENTS.
ES2594409T3 (en) Heteroaryl derivatives as modulators of nAChR á7
AR030959A1 (en) DERIVATIVES OF AMINOALCOHOLES, PROCEDURE TO PREPARE THEM, THE USE OF THE SAME TO PREPARE DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN104507481A (en) 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease
BRPI0616574A2 (en) sulfonamide derivative having pgd2 receptor antagonistic activity
BR0306208A (en) Dibenzylamine compounds and their pharmaceutical use
BR0311541A (en) indole, azaindole and 4-akenyl piperidine related heterocyclic amides
UY28578A1 (en) AMIDA DERIVATIVES
AR035774A1 (en) BENZIMIDAZOL AND PIRIDILIMIDAZOL DERIVATIVES, A PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND PACKAGES THAT UNDERSTAND THEM, THE USE OF SUCH COMPOUNDS ONLY OR IN COMBINATION FOR THE MANUFACTURE OF MEDICINES AS LIGANDOS FOR GABAAT TREATMENT, AND METHOD
CO5721006A2 (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCESS FOR ITS PREPARATION AND ITS USE AS QUINASE INHIBITORS
AR033344A1 (en) COMPOUNDS DERIVED FROM BENZOPHENONAS AS INHIBITORS OF THE INVERSE TRANSCRIPT, ITS USE IN THE MANUFACTURE OF MEDICINES, INTERMEDIARIES AND PHARMACEUTICAL COMPOSITIONS
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
BR0213790A (en) Aminobenzamide derivatives as glycogen synthase kinase 3beta inhibitors
BRPI0607600A2 (en) 4-oxoquinazolin-3-yl-benzamide derivatives for treatment of cytokine-related diseases
AR035374A1 (en) A PHENYLACETAMIDE-PIRAZOL DERIVATIVE, ITS USE, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A KIT THAT UNDERSTANDS SUCH DERIVATIVE OR COMPOSITION, A METHOD TO TREAT PROLIFERATIVE DISORDERS ASSOCIATED ASSOCIATED ASSOCIATED PARTNERS
AR055592A1 (en) DERIVATIVES OF 2-AMINO-5-CYCLALKYL-HYDANTOINE AS MODULATORS AND / OR INHIBITORS OF BETA-SECRETASE (BACE)
BR0014137A (en) Compound, method for inhibiting aurora 2 kinase in a warm-blooded animal, use of a compound, and pharmaceutical composition
AR043938A1 (en) HETEROCICLIC COMPOUND DERIVED FROM QUINOLINE OR NAFTIRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE THIS LAST

Legal Events

Date Code Title Description
FB Suspension of granting procedure